Oppenheimer & Co. Inc. Purchases 23,078 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Oppenheimer & Co. Inc. lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 28.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 104,487 shares of the biopharmaceutical company’s stock after purchasing an additional 23,078 shares during the period. Oppenheimer & Co. Inc.’s holdings in Catalyst Pharmaceuticals were worth $2,181,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Larson Financial Group LLC raised its holdings in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth about $65,000. KBC Group NV raised its stake in Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares during the period. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $134,000. Finally, Quantbot Technologies LP bought a new position in Catalyst Pharmaceuticals in the 3rd quarter worth approximately $151,000. Institutional investors own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CPRX. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Bank of America reissued a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Robert W. Baird assumed coverage on Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They set an “outperform” rating and a $28.00 price objective for the company. Finally, Truist Financial boosted their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $32.00.

Insiders Place Their Bets

In other news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Trading Up 5.7 %

Shares of NASDAQ CPRX opened at $22.89 on Monday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.47 and a 12-month high of $24.64. The firm’s 50-day moving average price is $22.24 and its 200-day moving average price is $21.44. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of 19.40, a P/E/G ratio of 3.31 and a beta of 0.80.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.